Bioconjugates of Chelators with Peptides and Proteins in Nuclear Medicine: Historical Importance, Current Innovations, and Future Challenges
Molecular radiopharmaceuticals based on bioconjugates of chelators with peptides and proteins have had significant clinical impact in the diagnosis and treatment of several types of cancers. In the 1990s, indium-111 and yttrium-90 labeled chelator-peptide/protein conjugates established the clinical...
Gespeichert in:
| Veröffentlicht in: | Bioconjugate chemistry 2020-03, Vol.31 (3), p.483-491 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 491 |
|---|---|
| container_issue | 3 |
| container_start_page | 483 |
| container_title | Bioconjugate chemistry |
| container_volume | 31 |
| creator | Jackson, Jessica A Hungnes, Ingebjørg N Ma, Michelle T Rivas, Charlotte |
| description | Molecular radiopharmaceuticals based on bioconjugates of chelators with peptides and proteins have had significant clinical impact in the diagnosis and treatment of several types of cancers. In the 1990s, indium-111 and yttrium-90 labeled chelator-peptide/protein conjugates established the clinical utility of these radiopharmaceuticals for receptor-targeted γ-scintigraphy imaging and systemic radiotherapy. Second-generation bioconjugates based on peptides targeting the somatostatin II receptor and the prostate-specific membrane antigen are now widely used for management of neuroendocrine and prostate cancer, respectively. These bioconjugates are typically radiolabeled with gallium-68 for imaging of target receptor expression with positron emission tomography, and the β–-emitter, lutetium-177, for targeted radiotherapy. Innovations in radioisotope technology and biomolecular therapies are likely to drive the future clinical development of radiopharmaceuticals based on radiometals. New chelator–peptide and chelator–protein bioconjugates will underpin nuclear medicine advances in molecular imaging and radiotherapy. |
| doi_str_mv | 10.1021/acs.bioconjchem.0c00015 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2348233514</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2391215931</sourcerecordid><originalsourceid>FETCH-LOGICAL-a434t-dde1eeacc89f6d8fbc3b81a20de53479aa317e9dd36d2b1f8df075f7c630f4963</originalsourceid><addsrcrecordid>eNqFkctuEzEUhi1ERUvhFcASGxad4NtkxuxKRGmkAl3AeuSxjxtHM3bwpRXvwEPjklChblgdS-f7v2PpR-g1JQtKGH2ndFqMLujgt3oD84JoQghtn6AT2jLSiJ6yp_VNBG9oT9gxep7StiKS9uwZOuZUStIKfoJ-fdhbyo3KkHCweLWBSeUQE75zeYOvYZedqSvlDb6OIYPzCTuPvxQ9gYr4MxinnYf3-NKlmnNaTXg970LMyms4w6sSI_iM196HW5Vd8Onsj-2i5BKhHlTTBP4G0gt0ZNWU4OVhnqLvFx-_rS6bq6-f1qvzq0YJLnJjDFAApXUv7dL0dtR87KlixEDLRSeV4rQDaQxfGjZS2xtLutZ2esmJFXLJT9HbvXcXw48CKQ-zSxqmSXkIJQ2Mi55x3lJR0TeP0G0o0dffVUpSRlvJaaW6PaVjSCmCHXbRzSr-HCgZ7gsbamHDP4UNh8Jq8tXBX8YZzEPub0MV4Hvg3vBw-3_a31T-qjc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2391215931</pqid></control><display><type>article</type><title>Bioconjugates of Chelators with Peptides and Proteins in Nuclear Medicine: Historical Importance, Current Innovations, and Future Challenges</title><source>ACS Publications</source><source>MEDLINE</source><creator>Jackson, Jessica A ; Hungnes, Ingebjørg N ; Ma, Michelle T ; Rivas, Charlotte</creator><creatorcontrib>Jackson, Jessica A ; Hungnes, Ingebjørg N ; Ma, Michelle T ; Rivas, Charlotte</creatorcontrib><description>Molecular radiopharmaceuticals based on bioconjugates of chelators with peptides and proteins have had significant clinical impact in the diagnosis and treatment of several types of cancers. In the 1990s, indium-111 and yttrium-90 labeled chelator-peptide/protein conjugates established the clinical utility of these radiopharmaceuticals for receptor-targeted γ-scintigraphy imaging and systemic radiotherapy. Second-generation bioconjugates based on peptides targeting the somatostatin II receptor and the prostate-specific membrane antigen are now widely used for management of neuroendocrine and prostate cancer, respectively. These bioconjugates are typically radiolabeled with gallium-68 for imaging of target receptor expression with positron emission tomography, and the β–-emitter, lutetium-177, for targeted radiotherapy. Innovations in radioisotope technology and biomolecular therapies are likely to drive the future clinical development of radiopharmaceuticals based on radiometals. New chelator–peptide and chelator–protein bioconjugates will underpin nuclear medicine advances in molecular imaging and radiotherapy.</description><identifier>ISSN: 1043-1802</identifier><identifier>EISSN: 1520-4812</identifier><identifier>DOI: 10.1021/acs.bioconjchem.0c00015</identifier><identifier>PMID: 31990543</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Animals ; Antigens ; Chelating agents ; Chelating Agents - chemistry ; Diagnostic Imaging ; Emitters ; Gallium ; Humans ; Indium ; Innovations ; Lutetium ; Medical imaging ; Medicine ; Nuclear medicine ; Nuclear Medicine - methods ; Peptides ; Peptides - chemistry ; Positron emission ; Positron emission tomography ; Prostate cancer ; Proteins ; Proteins - chemistry ; Radiation therapy ; Radioisotopes ; Radiopharmaceuticals - chemistry ; Radiopharmaceuticals - therapeutic use ; Receptors ; Scintigraphy ; Somatostatin ; Target recognition ; Topical Review ; Yttrium ; Yttrium isotopes</subject><ispartof>Bioconjugate chemistry, 2020-03, Vol.31 (3), p.483-491</ispartof><rights>Copyright American Chemical Society Mar 18, 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a434t-dde1eeacc89f6d8fbc3b81a20de53479aa317e9dd36d2b1f8df075f7c630f4963</citedby><cites>FETCH-LOGICAL-a434t-dde1eeacc89f6d8fbc3b81a20de53479aa317e9dd36d2b1f8df075f7c630f4963</cites><orcidid>0000-0002-3349-7346</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.bioconjchem.0c00015$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.bioconjchem.0c00015$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31990543$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jackson, Jessica A</creatorcontrib><creatorcontrib>Hungnes, Ingebjørg N</creatorcontrib><creatorcontrib>Ma, Michelle T</creatorcontrib><creatorcontrib>Rivas, Charlotte</creatorcontrib><title>Bioconjugates of Chelators with Peptides and Proteins in Nuclear Medicine: Historical Importance, Current Innovations, and Future Challenges</title><title>Bioconjugate chemistry</title><addtitle>Bioconjugate Chem</addtitle><description>Molecular radiopharmaceuticals based on bioconjugates of chelators with peptides and proteins have had significant clinical impact in the diagnosis and treatment of several types of cancers. In the 1990s, indium-111 and yttrium-90 labeled chelator-peptide/protein conjugates established the clinical utility of these radiopharmaceuticals for receptor-targeted γ-scintigraphy imaging and systemic radiotherapy. Second-generation bioconjugates based on peptides targeting the somatostatin II receptor and the prostate-specific membrane antigen are now widely used for management of neuroendocrine and prostate cancer, respectively. These bioconjugates are typically radiolabeled with gallium-68 for imaging of target receptor expression with positron emission tomography, and the β–-emitter, lutetium-177, for targeted radiotherapy. Innovations in radioisotope technology and biomolecular therapies are likely to drive the future clinical development of radiopharmaceuticals based on radiometals. New chelator–peptide and chelator–protein bioconjugates will underpin nuclear medicine advances in molecular imaging and radiotherapy.</description><subject>Animals</subject><subject>Antigens</subject><subject>Chelating agents</subject><subject>Chelating Agents - chemistry</subject><subject>Diagnostic Imaging</subject><subject>Emitters</subject><subject>Gallium</subject><subject>Humans</subject><subject>Indium</subject><subject>Innovations</subject><subject>Lutetium</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Nuclear medicine</subject><subject>Nuclear Medicine - methods</subject><subject>Peptides</subject><subject>Peptides - chemistry</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Prostate cancer</subject><subject>Proteins</subject><subject>Proteins - chemistry</subject><subject>Radiation therapy</subject><subject>Radioisotopes</subject><subject>Radiopharmaceuticals - chemistry</subject><subject>Radiopharmaceuticals - therapeutic use</subject><subject>Receptors</subject><subject>Scintigraphy</subject><subject>Somatostatin</subject><subject>Target recognition</subject><subject>Topical Review</subject><subject>Yttrium</subject><subject>Yttrium isotopes</subject><issn>1043-1802</issn><issn>1520-4812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctuEzEUhi1ERUvhFcASGxad4NtkxuxKRGmkAl3AeuSxjxtHM3bwpRXvwEPjklChblgdS-f7v2PpR-g1JQtKGH2ndFqMLujgt3oD84JoQghtn6AT2jLSiJ6yp_VNBG9oT9gxep7StiKS9uwZOuZUStIKfoJ-fdhbyo3KkHCweLWBSeUQE75zeYOvYZedqSvlDb6OIYPzCTuPvxQ9gYr4MxinnYf3-NKlmnNaTXg970LMyms4w6sSI_iM196HW5Vd8Onsj-2i5BKhHlTTBP4G0gt0ZNWU4OVhnqLvFx-_rS6bq6-f1qvzq0YJLnJjDFAApXUv7dL0dtR87KlixEDLRSeV4rQDaQxfGjZS2xtLutZ2esmJFXLJT9HbvXcXw48CKQ-zSxqmSXkIJQ2Mi55x3lJR0TeP0G0o0dffVUpSRlvJaaW6PaVjSCmCHXbRzSr-HCgZ7gsbamHDP4UNh8Jq8tXBX8YZzEPub0MV4Hvg3vBw-3_a31T-qjc</recordid><startdate>20200318</startdate><enddate>20200318</enddate><creator>Jackson, Jessica A</creator><creator>Hungnes, Ingebjørg N</creator><creator>Ma, Michelle T</creator><creator>Rivas, Charlotte</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3349-7346</orcidid></search><sort><creationdate>20200318</creationdate><title>Bioconjugates of Chelators with Peptides and Proteins in Nuclear Medicine: Historical Importance, Current Innovations, and Future Challenges</title><author>Jackson, Jessica A ; Hungnes, Ingebjørg N ; Ma, Michelle T ; Rivas, Charlotte</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a434t-dde1eeacc89f6d8fbc3b81a20de53479aa317e9dd36d2b1f8df075f7c630f4963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Antigens</topic><topic>Chelating agents</topic><topic>Chelating Agents - chemistry</topic><topic>Diagnostic Imaging</topic><topic>Emitters</topic><topic>Gallium</topic><topic>Humans</topic><topic>Indium</topic><topic>Innovations</topic><topic>Lutetium</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Nuclear medicine</topic><topic>Nuclear Medicine - methods</topic><topic>Peptides</topic><topic>Peptides - chemistry</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Prostate cancer</topic><topic>Proteins</topic><topic>Proteins - chemistry</topic><topic>Radiation therapy</topic><topic>Radioisotopes</topic><topic>Radiopharmaceuticals - chemistry</topic><topic>Radiopharmaceuticals - therapeutic use</topic><topic>Receptors</topic><topic>Scintigraphy</topic><topic>Somatostatin</topic><topic>Target recognition</topic><topic>Topical Review</topic><topic>Yttrium</topic><topic>Yttrium isotopes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jackson, Jessica A</creatorcontrib><creatorcontrib>Hungnes, Ingebjørg N</creatorcontrib><creatorcontrib>Ma, Michelle T</creatorcontrib><creatorcontrib>Rivas, Charlotte</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Bioconjugate chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jackson, Jessica A</au><au>Hungnes, Ingebjørg N</au><au>Ma, Michelle T</au><au>Rivas, Charlotte</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bioconjugates of Chelators with Peptides and Proteins in Nuclear Medicine: Historical Importance, Current Innovations, and Future Challenges</atitle><jtitle>Bioconjugate chemistry</jtitle><addtitle>Bioconjugate Chem</addtitle><date>2020-03-18</date><risdate>2020</risdate><volume>31</volume><issue>3</issue><spage>483</spage><epage>491</epage><pages>483-491</pages><issn>1043-1802</issn><eissn>1520-4812</eissn><abstract>Molecular radiopharmaceuticals based on bioconjugates of chelators with peptides and proteins have had significant clinical impact in the diagnosis and treatment of several types of cancers. In the 1990s, indium-111 and yttrium-90 labeled chelator-peptide/protein conjugates established the clinical utility of these radiopharmaceuticals for receptor-targeted γ-scintigraphy imaging and systemic radiotherapy. Second-generation bioconjugates based on peptides targeting the somatostatin II receptor and the prostate-specific membrane antigen are now widely used for management of neuroendocrine and prostate cancer, respectively. These bioconjugates are typically radiolabeled with gallium-68 for imaging of target receptor expression with positron emission tomography, and the β–-emitter, lutetium-177, for targeted radiotherapy. Innovations in radioisotope technology and biomolecular therapies are likely to drive the future clinical development of radiopharmaceuticals based on radiometals. New chelator–peptide and chelator–protein bioconjugates will underpin nuclear medicine advances in molecular imaging and radiotherapy.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>31990543</pmid><doi>10.1021/acs.bioconjchem.0c00015</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-3349-7346</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-1802 |
| ispartof | Bioconjugate chemistry, 2020-03, Vol.31 (3), p.483-491 |
| issn | 1043-1802 1520-4812 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2348233514 |
| source | ACS Publications; MEDLINE |
| subjects | Animals Antigens Chelating agents Chelating Agents - chemistry Diagnostic Imaging Emitters Gallium Humans Indium Innovations Lutetium Medical imaging Medicine Nuclear medicine Nuclear Medicine - methods Peptides Peptides - chemistry Positron emission Positron emission tomography Prostate cancer Proteins Proteins - chemistry Radiation therapy Radioisotopes Radiopharmaceuticals - chemistry Radiopharmaceuticals - therapeutic use Receptors Scintigraphy Somatostatin Target recognition Topical Review Yttrium Yttrium isotopes |
| title | Bioconjugates of Chelators with Peptides and Proteins in Nuclear Medicine: Historical Importance, Current Innovations, and Future Challenges |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T12%3A33%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bioconjugates%20of%20Chelators%20with%20Peptides%20and%20Proteins%20in%20Nuclear%20Medicine:%20Historical%20Importance,%20Current%20Innovations,%20and%20Future%20Challenges&rft.jtitle=Bioconjugate%20chemistry&rft.au=Jackson,%20Jessica%20A&rft.date=2020-03-18&rft.volume=31&rft.issue=3&rft.spage=483&rft.epage=491&rft.pages=483-491&rft.issn=1043-1802&rft.eissn=1520-4812&rft_id=info:doi/10.1021/acs.bioconjchem.0c00015&rft_dat=%3Cproquest_cross%3E2391215931%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2391215931&rft_id=info:pmid/31990543&rfr_iscdi=true |